Pharmacological restriction of genomic binding sites redirects PU.1 pioneer transcription factor activity

通过药物手段限制基因组结合位点可改变PU.1先锋转录因子的活性

阅读:3
作者:Samuel J Taylor ,Jacob Stauber ,Oliver Bohorquez ,Goichi Tatsumi ,Rajni Kumari ,Joyeeta Chakraborty ,Boris A Bartholdy ,Emily Schwenger ,Sriram Sundaravel ,Abdelbasset A Farahat ,Justin C Wheat ,Mendel Goldfinger ,Amit Verma ,Arvind Kumar ,David W Boykin ,Kristy R Stengel ,Gregory M K Poon ,Ulrich Steidl

Abstract

Transcription factor (TF) DNA-binding dynamics govern cell fate and identity. However, our ability to pharmacologically control TF localization is limited. Here we leverage chemically driven binding site restriction leading to robust and DNA-sequence-specific redistribution of PU.1, a pioneer TF pertinent to many hematopoietic malignancies. Through an innovative technique, 'CLICK-on-CUT&Tag', we characterize the hierarchy of de novo PU.1 motifs, predicting occupancy in the PU.1 cistrome under binding site restriction. Temporal and single-molecule studies of binding site restriction uncover the pioneering dynamics of native PU.1 and identify the paradoxical activation of an alternate target gene set driven by PU.1 localization to second-tier binding sites. These transcriptional changes were corroborated by genetic blockade and site-specific reporter assays. Binding site restriction and subsequent PU.1 network rewiring causes primary human leukemia cells to differentiate. In summary, pharmacologically induced TF redistribution can be harnessed to govern TF localization, actuate alternate gene networks and direct cell fate.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。